Clinical trials: ST Elevation Myocardial Infarction (STEMI)
Myocardial Infarction
Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.
- Trial name
- NCT00883727
- Testing
- Stem cell, Plasmalyte A
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Stempeutics Research Pvt Ltd
STEMI (ST Elevation MI)
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
The goal of this interventional study is to evaluate if the CoFI system can act as a platform for intracoronary infusion of therapeutic agents to treat and relieve microvascular injury in ST Elevation Acute Coronary Syndrome…
- Trial name
- REVITALISE (NCT06935383)
- Testing
- Therapeutic sequence, Diagnostic sequence
- Volunteers
- 250 people
- Sponsor
- CorFlow Therapeutics AG
STEMI
STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)
Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the struts to the vessel wall than a balloon-expandable stent within a few days after the procedure in acute myocardial infarction patients.
- Trial name
- APPOSITION ll (NCT01008085)
- Testing
- Stentys coronary stent, Balloon-expandable stent
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Stentys
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Acute Myocardial Infarction, Acute Myocardial Ischemia
Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
- Conditions
- Acute Myocardial Infarction, Acute Myocardial Ischemia, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT03486080
- Testing
- Dutogliptin Tartrate, Filgrastim Injectable Product
- Where
- 12 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Recardio, Inc.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Hungary Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
- Trial name
- NCT01892917
- Where
- 13 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- Biotronik Hungária Kft.
Safety Issues
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment…
- Trial name
- NCT05724576
- Testing
- OmniMSC-AMI
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Taiwan Bio Therapeutics Inc.
Acute ST Segment Elevation Myocardial Infarction
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial…
- Trial name
- NCT04463251
- Testing
- RPH-104 80 mg
- Where
- 11 sites in United States, Russia
- Volunteers
- 102 people
- Sponsor
- R-Pharm Overseas, Inc.
Coronary Artery Disease
ST Segment Detection Study
The purpose of ST Detect study is to evaluate whether naturally occurring spontaneous coronary events and exercise induced cardiac ischemia, give rise to detectable changes on intracardiac electrogram (EGM) signals in patients…
- Trial name
- ST Detect (NCT00930969)
- Testing
- ICD
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Survival Myocardial Area After Acute Myocardial Death, Left Ventricular Ejection Fraction
Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI
In this study, advanced techniques of myocardial nuclear magnetic perfusion scanning were used to quantitatively assess infarct size after acute myocardial infarction, saved viable myocardium, and microcirculatory obstruction…
- Trial name
- NCT03958422
- Testing
- cardiomyopeptidin
- Volunteers
- 160 people
- Sponsor
- Dalian Zhen-Ao Bio-Tech Co., Ltd.
Acute Coronary Syndromes
Finding Acute Coronary Syndromes (ACS) With Serial Troponin Testing for Rapid Assessment of Cardiac Ischemic Symptoms
Study Objectives The following items will be prospectively assessed. Primary Endpoints 1. For patients presenting with clinical suspicion of Acute Coronary Syndromes (ACS), high sensitivity-cardiac Troponin I (hs-cTnI) provides…
- Trial name
- FAST-TRAC (NCT00880802)
- Where
- 16 sites in United States, Greece and 2 more
- Volunteers
- 1,500 people
- Sponsor
- Nanosphere, Inc.
Myocardial Infarction (MI)
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
Thi is is a multi-center, randomized, single-blind, parallel group clinical trial to evaluate the efficacy and safety of the intravenious thrombolysis with Revelise® (GENERIUM, Russia) in comparosin with the Actilyse® (Boehringer…
- Trial name
- NCT07146360
- Testing
- Revelise (GENERIUM, Russia), Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Where
- 22 sites in Russia
- Volunteers
- 180 people
- Sponsor
- AO GENERIUM
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
Myocardial Infarction
the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.
This study focused on the effect of Danhong injection on microcirculation in the treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.
- Trial name
- Danhong (NCT02158559)
- Testing
- Danhong Injection, Normal Saline
- Volunteers
- 180 people
- Sponsor
- Beijing Bozhiyin T&S Co., Ltd.
Acute Coronary Syndrome
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
Losmapimod is a new anti-inflammatory medication which potentially may benefit patients with Acute Coronary Syndrome, (ACS), a condition which includes heart attack.
- Trial name
- LATITUDE (NCT02145468)
- Testing
- Losmapimod 7.5 mg twice daily, Standard therapy
- Where
- 341 sites in United States, Argentina and 32 more
- Volunteers
- 3,503 people
- Sponsor
- GlaxoSmithKline
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarct
Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)
Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary percutaneous cardiac intervention will following the standard treatment , received low dose of Ilomedin and to low dose of standard…
- Trial name
- NCT01179776
- Testing
- Ilomedin, Ilomedin and standard low dose treatment
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Thrombologic ApS
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.
Cardiogenic Shock
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%.
- Trial name
- Corvad AMICS (NCT06886113)
- Testing
- Conventional circulatory support, CorVad
- Where
- China
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
ST-segment Elevation Myocardial Infarction
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
- Trial name
- NCT02070471
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- LG Life Sciences